The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.
Medicine by Design, in partnership with the McEwen Stem Cell Institute, is pleased to welcome Miriam Merad, MD, PhD. Miriam Merad is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Talk title: Targeting myeloid cells in cancer and inflammatory diseases
This is a virtual event.
- Virtual event links will be sent after registration.
About Miriam Merad
Dr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue-resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on developing novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, which control adaptive immunity. She identified a new subset of dendritic cells, now considered a key antiviral and antitumor immunity target.
Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology, medicine, technology, physics, mathematics, and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai, one of the world’s most sophisticated research centers, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses.
Dr. Merad has authored more than 200 primary papers and reviews in high-profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and its contribution to human disease and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President of the International Union of Immunological Societies (IUIS). In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.